Monitor for future financial disclosures that may reflect the cost of this executive hire; watch for potential stock dilution from RSU issuance once Form S-8 is filed.
Price Chart
Executive Summary
Artiva Biotherapeutics appointed Thad Huston as Chief Financial Officer effective February 18, 2026. Huston receives an annual base salary of $540,000 and an inducement grant of 220,000 restricted stock units, with vesting over four years. The appointment reflects a strategic leadership addition in the biotech firm's financial management.
Key Facts
- Thad Huston appointed CFO effective February 18, 2026
- Annual base salary of $540,000 with 40% target bonus
- Inducement grant of 220,000 RSUs under 2025 Inducement Plan
- RSUs vest over four years: 25% on February 15, 2027, then quarterly
- Employment Agreement includes severance terms for termination without Cause or for Good Reason
Financial Impact
Approximately $540,000 annual cash compensation plus $2.2 million in RSUs (based on current market value assumptions, not disclosed in filing)
Risk Factors
- Potential dilution from issuance of 220,000 RSUs
- Leadership transition risk during integration period
- Increased operating expenses from new executive compensation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (ARTV) — Batch item 1 | 0001193125-26-067509 |
| Document: 0001193125-26-067509-index-headers.html | 0001193125-26-067509 |
| Document: 0001193125-26-067509-index.html | 0001193125-26-067509 |
| Document: 0001193125-26-067509.txt | 0001193125-26-067509 |
| 8-K Filing (ARTV) — Batch item 5 | 0001193125-26-067509 |
| Document: 0001193125-26-067509-index-headers.html | 0001193125-26-067509 |
| Document: 0001193125-26-067509-index.html | 0001193125-26-067509 |
| Document: 0001193125-26-067509.txt | 0001193125-26-067509 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.87 (−32.25%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.87 (−36.33%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.87 (−36.33%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.87 (−36.33%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.87 (−36.33%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.87 (+36.33%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.87 (−38.61%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.87 (−41.48%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.87 (−36.15%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.87 (−34.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access